NASDAQ:MEIP MEI Pharma (MEIP) Stock Price, News & Analysis → $25,000 into $109,616 in two months? (From WealthPress) (Ad) Free MEIP Stock Alerts $3.95 +0.09 (+2.33%) (As of 03/27/2024 ET) Add Compare Share Share Today's Range$3.86▼$3.9550-Day Range$3.54▼$4.9352-Week Range$3.46▼$7.97Volume10,288 shsAverage Volume27,441 shsMarket Capitalization$26.31 millionP/E Ratio1.33Dividend YieldN/APrice Target$7.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get MEI Pharma alerts: Email Address MEI Pharma MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/Downside77.2% Upside$7.00 Price TargetShort InterestHealthy0.15% of Float Sold ShortDividend StrengthN/ASustainability-0.86Upright™ Environmental ScoreNews Sentiment0.71Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom $3.24 to ($4.98) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.44 out of 5 starsMedical Sector144th out of 939 stocksPharmaceutical Preparations Industry55th out of 434 stocks 3.0 Analyst's Opinion Consensus RatingMEI Pharma has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $7.00, MEI Pharma has a forecasted upside of 77.2% from its current price of $3.95.Amount of Analyst CoverageMEI Pharma has only been the subject of 1 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.15% of the float of MEI Pharma has been sold short.Short Interest Ratio / Days to CoverMEI Pharma has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in MEI Pharma has recently decreased by 27.20%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldMEI Pharma does not currently pay a dividend.Dividend GrowthMEI Pharma does not have a long track record of dividend growth. Previous Next 4.3 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreMEI Pharma has received a 65.21% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for cancer" product. See details.Environmental SustainabilityThe Environmental Impact score for MEI Pharma is -0.86. Previous Next 2.6 News and Social Media Coverage News SentimentMEI Pharma has a news sentiment score of 0.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for MEI Pharma this week, compared to 1 article on an average week.Search InterestOnly 5 people have searched for MEIP on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added MEI Pharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, MEI Pharma insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.90% of the stock of MEI Pharma is held by insiders.Percentage Held by Institutions52.38% of the stock of MEI Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for MEI Pharma are expected to decrease in the coming year, from $3.24 to ($4.98) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of MEI Pharma is 1.33, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 136.68.Price to Earnings Ratio vs. SectorThe P/E ratio of MEI Pharma is 1.33, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 188.96.Price to Book Value per Share RatioMEI Pharma has a P/B Ratio of 1.07. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Insiders ExposedThis consistently signaled gains of 453%... 610%... and even 1036%...It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.Register for the imminent briefing here. About MEI Pharma Stock (NASDAQ:MEIP)MEI Pharma, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor for the treatment of patients with relapsed/refractory follicular lymphoma; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase I clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex which has completed Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer. MEI Pharma, Inc. has a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.Read More MEIP Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MEIP Stock News HeadlinesMarch 26, 2024 | finance.yahoo.comMEI Pharma Reports Update from Clinical Study Evaluating Oral CDK9 Inhibitor Voruciclib in Combination with Venetoclax in Patients with Relapsed and Refractory Acute Myeloid LeukemiaMarch 23, 2024 | americanbankingnews.comMEI Pharma (NASDAQ:MEIP) Shares Cross Below 200-Day Moving Average of $5.71March 28, 2024 | WealthPress (Ad)$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…March 20, 2024 | stocknews.com3 Pharma Stocks Outperforming the CompetitionMarch 20, 2024 | americanbankingnews.comInnovus Pharmaceuticals (OTCMKTS:INNVD) & MEI Pharma (NASDAQ:MEIP) Financial ContrastMarch 3, 2024 | investing.comMEI Pharma Inc (MEIP)February 29, 2024 | seekingalpha.comMEIP MEI Pharma, Inc.February 15, 2024 | businesswire.comGlancy Prongay & Murray LLP Announces Investigation of MEI Pharma, Inc. (MEIP)March 28, 2024 | DTI (Ad)Warning: this could blow your mindBuckle up… ‘Cause this might shatter everything you’ve heard about “income trading”. In fact, it’s such an extreme diversion from what most people think of typical income trades that I call it: The Perfect Income Trade You see, most of the income techniques out there target a couple of percent. Maybe 5 - 10 percent if you’re lucky. But this new way of trading income on the world’s top stocks goes after more than 10x that kind of return. And here’s the best news of all: This trade can target an opportunity like that every week. Every single week. Meaning an investor has the chance to “stack up” these more aggressive income trades over and over. If that sounds interesting…February 15, 2024 | businesswire.comGlancy Prongay & Murray LLP Announces Investigation of MEI Pharma, Inc. (MEIP)February 13, 2024 | finance.yahoo.comMEI Pharma Reports Second Quarter Fiscal Year 2024 Results and Operational HighlightsFebruary 13, 2024 | finance.yahoo.comMEI Pharma, Inc. (MEIP) Reports Q2 Loss, Misses Revenue EstimatesFebruary 13, 2024 | businesswire.comMEI Pharma Reports Second Quarter Fiscal Year 2024 Results and Operational HighlightsFebruary 8, 2024 | wsj.comMEI Pharma Inc.February 8, 2024 | finance.yahoo.comIs MEI Pharma (MEIP) Attractively Priced?January 18, 2024 | forbes.comAcceleron PharmaJanuary 16, 2024 | finance.yahoo.comMEI Pharma to Present Design of Ongoing Clinical Study Evaluating ME-344 at ASCO GI Cancers Symposium 2024December 27, 2023 | benzinga.comMEI Pharma Stock (NASDAQ:MEIP), Short Interest ReportDecember 27, 2023 | benzinga.comMEI Pharma Stock (NASDAQ:MEIP) Dividends: History, Yield and DatesDecember 11, 2023 | finance.yahoo.comMEI Pharma Reports Clinical Data on Oral CDK9 Inhibitor Voruciclib at ASH2023November 16, 2023 | markets.businessinsider.comStifel Nicolaus Reaffirms Their Hold Rating on MEI Pharma (MEIP)November 14, 2023 | morningstar.comMEI Pharma Inc MEIPNovember 9, 2023 | finance.yahoo.comMEI Pharma Reports First Quarter Fiscal Year 2024 Results and Operational HighlightsNovember 8, 2023 | finance.yahoo.comMEI Pharma to Present at the Stifel 2023 Healthcare ConferenceNovember 6, 2023 | finance.yahoo.comMEI Pharma Declares Special Cash Dividend of $1.75 Per Share of Common StockNovember 2, 2023 | finance.yahoo.comMEI Pharma Announces Acceptance of Abstract for Presentation at ASH 2023November 1, 2023 | finance.yahoo.comMEI Pharma Enters into Agreement with Anson Funds and Cable Car CapitalSee More Headlines Receive MEIP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MEI Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/13/2024Today3/28/2024Next Earnings (Estimated)5/09/2024Fiscal Year End6/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:MEIP Previous SymbolNASDAQ:MSHL CUSIPN/A CIK1262104 Webwww.meipharma.com Phone(858) 369-7100Fax302-655-5049Employees46Year FoundedN/APrice Target and Rating Average Stock Price Target$7.00 High Stock Price Target$7.00 Low Stock Price Target$7.00 Potential Upside/Downside+77.2%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)$2.97 Trailing P/E Ratio1.33 Forward P/E Ratio1.22 P/E GrowthN/ANet Income$-31,840,000.00 Net Margins39.06% Pretax Margin27.32% Return on Equity39.72% Return on Assets18.26% Debt Debt-to-Equity RatioN/A Current Ratio8.23 Quick Ratio8.23 Sales & Book Value Annual Sales$48.82 million Price / Sales0.54 Cash FlowN/A Price / Cash FlowN/A Book Value$3.70 per share Price / Book1.07Miscellaneous Outstanding Shares6,660,000Free Float6,403,000Market Cap$26.31 million OptionableOptionable Beta0.78 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. David M. Urso B.A. (Age 60)Esq., J.D., CEO, President & Director Comp: $748.46kDr. Richard G. Ghalie M.D. (Age 66)MBA, Chief Medical Officer Comp: $627.76kMr. Justin J. File (Age 54)CFO & Corporate Secretary Ms. Yomara Gomez-NaidenSenior Vice President of Operations & QualityMs. Nicole Chyoko IidaVice President of Legal AffairsMs. Anne FreseChief People OfficerDr. Robert D. Mass (Age 70)Strategic Advisor Comp: $201.68kMr. David A. Walsey J.D.L.L.M., Senior Vice President of Corporate AffairsMore ExecutivesKey CompetitorsSensei BiotherapeuticsNASDAQ:SNSEForte BiosciencesNASDAQ:FBRXLisata TherapeuticsNASDAQ:LSTALipocineNASDAQ:LPCNOrgenesisNASDAQ:ORGSView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 6,260 shares on 3/11/2024Ownership: 5.850%Cable Car Capital LLCBought 611,440 shares on 2/20/2024Ownership: 9.181%Vanguard Group Inc.Bought 6,260 shares on 2/15/2024Ownership: 5.853%Bridgeway Capital Management LLCBought 8,500 shares on 2/15/2024Ownership: 0.403%Northern Trust CorpBought 14,230 shares on 2/13/2024Ownership: 0.372%View All Insider TransactionsView All Institutional Transactions MEIP Stock Analysis - Frequently Asked Questions Should I buy or sell MEI Pharma stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for MEI Pharma in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" MEIP shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MEIP, but not buy additional shares or sell existing shares. View MEIP analyst ratings or view top-rated stocks. What is MEI Pharma's stock price target for 2024? 1 equities research analysts have issued 12 month price objectives for MEI Pharma's stock. Their MEIP share price targets range from $7.00 to $7.00. On average, they predict the company's share price to reach $7.00 in the next year. This suggests a possible upside of 77.2% from the stock's current price. View analysts price targets for MEIP or view top-rated stocks among Wall Street analysts. How have MEIP shares performed in 2024? MEI Pharma's stock was trading at $5.80 at the start of the year. Since then, MEIP shares have decreased by 31.9% and is now trading at $3.95. View the best growth stocks for 2024 here. Are investors shorting MEI Pharma? MEI Pharma saw a decline in short interest in March. As of March 15th, there was short interest totaling 9,100 shares, a decline of 27.2% from the February 29th total of 12,500 shares. Based on an average daily volume of 25,400 shares, the days-to-cover ratio is currently 0.4 days. Currently, 0.2% of the shares of the stock are sold short. View MEI Pharma's Short Interest. When is MEI Pharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our MEIP earnings forecast. How were MEI Pharma's earnings last quarter? MEI Pharma, Inc. (NASDAQ:MEIP) issued its earnings results on Tuesday, February, 13th. The company reported ($1.66) earnings per share for the quarter, missing analysts' consensus estimates of ($1.46) by $0.20. MEI Pharma had a trailing twelve-month return on equity of 39.72% and a net margin of 39.06%. How often does MEI Pharma pay dividends? What is the dividend yield for MEI Pharma? MEI Pharma declared a dividend on Monday, November 6th. Shareholders of record on Friday, November 17th will be paid a dividend of $1.75 per share on Wednesday, December 6th. The ex-dividend date is Thursday, November 16th. Read our dividend analysis for MEIP. When did MEI Pharma's stock split? Shares of MEI Pharma reverse split on the morning of Monday, April 17th 2023. The 1-20 reverse split was announced on Monday, April 17th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, April 17th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of MEI Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other MEI Pharma investors own include Inovio Pharmaceuticals (INO), Rigel Pharmaceuticals (RIGL), Gilead Sciences (GILD), Novavax (NVAX), Dynavax Technologies (DVAX), SCYNEXIS (SCYX), OPKO Health (OPK), VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE) and TherapeuticsMD (TXMD). Who are MEI Pharma's major shareholders? MEI Pharma's stock is owned by many different retail and institutional investors. Top institutional investors include Cable Car Capital LLC (9.18%), Vanguard Group Inc. (5.85%), Vanguard Group Inc. (5.85%), Bridgeway Capital Management LLC (0.40%), Northern Trust Corp (0.37%) and National Bank of Canada FI (0.09%). Insiders that own company stock include Anson Funds Management Lp and Charles V Baltic III. View institutional ownership trends. How do I buy shares of MEI Pharma? Shares of MEIP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:MEIP) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisorySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceBuy this small stock before coming AI Tidal WaveChaikin AnalyticsThe 3rd Revolution in WarfareWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MEI Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.